Search
forLearn
5 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
Research
5 / 319 resultsresearch Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital
HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.
research Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
research Androgen receptor: A promising therapeutic target in breast cancer
The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
research Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
research Targeted delivery of extracellular vesicles: the mechanisms, techniques and therapeutic applications
Engineered extracellular vesicles show promise for targeted therapy but need more research for clinical use.
Community Join
5 / 1000+ resultscommunity HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.